延迟性化疗相关性恶心呕吐的治疗进展  

Progression in the treatment of delayed chemotherapy-induced nausea and vomiting

作　　者：王盈[1] 林英城[1] 

机构地区：[1]汕头大学医学院附属肿瘤医院内科,广东汕头515031

出　　处：《临床肿瘤学杂志》2014年第10期945-949,共5页Chinese Clinical Oncology

摘　　要：化疗相关性恶心呕吐(CINV)严重影响肿瘤患者的生活质量。随着止呕药物的发展,急性、延迟性CINV的控制率较前已有明显升高,但延迟性CINV的控制率仍偏低。第1代5-羟色胺3(5-HT3)受体拮抗剂对延迟性CINV的控制率并不优于单用地塞米松、甲氧氯普胺和丙氯拉嗪。最近研究表明第2代5-HT3受体拮抗剂帕洛诺司琼、神经激肽1受体拮抗剂在控制延迟性CINV方面上优于第1代5-HT3受体拮抗剂,当其联合抗精神病药物如奥氮平、丙氯拉嗪等可明显提高延迟性CINV的控制率。本文对延迟性化疗相关性恶心呕吐的治疗进展作一综述。Chemotherapy-induced nausea and vomiting（ CINV） is associated with a significant deterioration in quality of life. With the development of antiemetic drugs, the control rate of acute and delayed CINV has significantly improved,but the control rate of delayed CINV is still low. The effect of first generations of 5-hydroxytryptamine-3（5-HT3） receptor antagonists are not significantly su-perior to dexamethasone, metoclopramide or prochlorperazine alone in the control of delayed CINV. Recent studies have shown that pal-onosetron, the second generation of 5-HT3 receptor antagonists, and NK-1 receptor antagonists are better than the first generation of 5-HT3 receptor antagonists in the prevention of delayed CINV. Combination with antipsychotics drugs such as olanzapine, prochlorperazine can effectively control delayed CINV.

关 键 词：化疗相关性恶心呕吐 延迟性 治疗 

分 类 号：R730.5[医药卫生—肿瘤]